Swiss Longitudinal Cohort
ConditionCardiovascular Risk Factors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6+
SponsorHypertension Excellence Centre Lucerne
About this trial
The planned research project is a prospective population-based cohort study, similar to the well-known Framingham study in the United States. So far, there is no similar research project in Switzerland.
It is planned to examine of three Swiss municipalities. Recruitment in a first Swiss municipality (Lostallo/Cama GR) started 2014 and ended in 2019. Overall, 496 participants were recruited in this municipality. The five-year follow-up in this municipality started in 2019. It is planned to start recruitment in a second Swiss municipality (Uznach SG) in 2020.
The examinations embrace a broad spectrum of measurements (for details the investigators refer to the published study protocol).
Eligibility criteria
Qualifiers
Resident of Cama GR, Lostallo GR, or Uznach SG
Age ≥6 years (no upper age limit), for voluntary blood sample ≥18 years
Willing to participate in long-term study
Written informed consent (in participants ≥6 years and <18 years signed by parents)
Disqualifiers
No exclusion criteria
Trial design
Treatments tested in this trial
- No intervention
Treatment groups
No treatment groups listed
Locations
3Linth Hospital8730, UznachCanton of St. Gallen, Switzerland
CamaCH-6557, CamaKanton Graubünden, Switzerland
LostalloCH-6558, LostalloKanton Graubünden, Switzerland
Sponsors and collaborators
Hypertension Excellence Centre Lucerne
Lead sponsor
Source ClinicalTrials.gov